malaria
tropic
diseas
common
africa
south
east
asia
south
america
million
clinic
case
malaria
year
estim
million
death
result
malaria
death
occur
children
five
year
old
malaria
caus
blood
parasit
plasmodium
speci
p
falciparum
widespread
danger
plasmodium
lead
host
death
burden
malaria
current
increas
drug
insecticid
resist
social
environment
chang
far
import
factor
develop
resist
p
falciparum
cheap
effect
drug
like
chloroquin
cq
fact
compound
market
encount
chemoresist
current
world
health
organ
recommend
artemisinin
art
combin
therapi
act
treatment
malaria
inde
combin
therapi
prefer
monotherapi
prevent
develop
resist
parasit
art
therapi
associ
drug
antimalari
longer
mefloquin
mf
nevertheless
continu
research
need
develop
new
antimalari
drug
induc
resist
conveni
approach
antimalari
drug
discoveri
base
modif
drug
encount
resist
problem
altern
attach
organometal
complex
organ
scaffold
alreadi
attempt
year
idea
use
organ
scaffold
drug
primari
properti
permeabl
uptak
transport
bind
target
organometal
moieti
alter
unwant
properti
resist
andor
optim
initi
ferrocen
fc
sandwich
structur
rapidli
identifi
metallocen
choic
inde
fc
small
rigid
lipophil
molecul
penetr
cellular
membran
fc
stabl
aqueou
aerob
media
allow
access
larg
varieti
deriv
addit
electrochem
behavior
fc
make
attract
biolog
applic
especi
drug
among
numer
ferrocen
bioconjug
one
famou
exampl
structur
variat
anticanc
drug
tamoxifen
give
anoth
one
ferroceron
develop
treat
iron
defici
anemia
use
market
minireview
focus
mainli
discoveri
ferroquin
fq
figur
new
antimalari
includ
effort
understand
mechan
action
resist
tabl
cq
figur
drug
long
use
treatment
prevent
malaria
although
mechan
action
partial
understood
therapeut
effect
attribut
abil
preferenti
concentr
food
vacuol
parasit
inhibit
format
malari
pigment
hemozoin
resist
cq
first
report
columbia
thailand
earli
worldwid
parasit
expel
cq
much
rapidli
red
blood
cell
parasit
mani
observ
indic
p
falciparum
transmembran
protein
pfcrt
involv
mutat
pfcrt
describ
p
falciparum
isol
combin
cq
structur
moieti
known
target
parasit
ferrocen
led
design
fq
first
organometal
antimalari
see
research
program
ferrocen
analogu
synthes
screen
group
professor
chibal
cape
town
south
africa
also
assist
us
research
nevertheless
far
none
compound
prove
better
fq
envisag
structur
design
respect
main
properti
cq
local
food
vacuol
parasit
propens
inhibit
hemozoin
format
besid
less
convent
design
also
investig
could
exclud
modif
parent
drug
might
lead
novel
properti
altern
mechan
action
first
tempt
simpli
associ
cq
ferrocenecarboxyl
acid
weak
interact
compound
inde
ferrocen
moieti
may
independ
potenti
activ
cq
enhanc
oxid
stress
nevertheless
hypothesi
proven
wrong
vitro
test
reveal
salt
even
less
activ
cq
diphosph
suggest
antagonist
effect
part
format
quaternari
ammonium
salt
direct
condens
ferrocenylmethyl
fem
moieti
endocycl
nitrogen
cq
core
abolish
activ
parent
molecul
cq
resist
sensit
p
falciparum
charg
speci
abl
cross
membran
low
vitro
activ
also
observ
compound
quinolin
cycl
substitut
posit
bulki
ferrocenyl
group
steric
hinder
stack
interact
quinolin
ring
heme
particular
attent
devot
studi
impact
introduct
ferrocenyl
moieti
later
side
chain
cq
inde
length
side
chain
distanc
two
exocycl
nitrogen
atom
may
affect
resist
p
shorter
two
three
carbon
atom
longer
side
chain
carbon
atom
cq
activ
p
falciparum
suggest
molecul
space
less
suit
bind
put
cq
transport
therefor
less
effici
extrud
food
vacuol
seri
cq
analogu
character
presenc
ferrocenyl
group
attach
termin
nitrogen
atom
cq
later
chain
synthes
wherea
analogu
found
activ
cq
offer
rel
disappoint
activ
compar
fq
compound
show
activ
decreas
rapidli
level
among
p
falciparum
clone
test
clearli
cross
resist
could
postul
emerg
quickli
signific
correl
either
liphophil
charact
vitro
inhibit
hemozoin
format
valu
among
cq
analogu
conjug
compound
rfem
led
errat
activ
imposs
measur
precis
valu
stabil
solubl
problem
cultur
decreas
efficaci
observ
linear
branch
propylamino
chain
deriv
introduct
methyl
group
side
chain
favor
antimalari
contrari
presenc
ferrocen
moieti
within
later
chain
fq
analogu
main
condit
retain
strong
antimalari
activ
p
falciparum
fq
analogu
exhibit
antimalari
activ
much
stronger
cq
strain
except
second
ferrocenyl
group
introduc
termin
nitrogen
atom
efficaci
compound
markedli
substitut
ferrocen
chiral
molecul
effort
made
design
achir
version
deriv
easiest
solut
move
second
substitu
cyclopentadienyl
cycl
achir
ferrocen
analogu
exhibit
lower
activ
cq
resist
strain
cq
sensit
nervertheless
vivo
data
avail
comparison
substitut
pattern
versu
similar
trend
also
observ
deriv
artemesinin
show
better
antimalari
activ
parent
compound
analogu
obtain
two
separ
stereoisom
racem
prepar
artemisiten
figur
deriv
exhibit
valu
p
falciparum
tenfold
lower
artemisiten
similar
deriv
stereoisom
racem
racem
stereoisom
synthes
merg
ferrocen
artemisinin
via
ester
bond
like
artesun
structur
via
ether
bond
like
artemeth
skeleton
produc
increas
antimalari
activ
compar
dihydroartemisinin
conclud
incorpor
ferrocen
moieti
artemesinin
skeleton
improv
activ
use
strategi
similar
design
fq
quinuclidinyl
piperidinyl
side
chain
quinin
mefloquin
mf
respect
substitut
ferrocen
moieti
maintain
basic
amino
group
figur
vitro
lower
activ
parent
compound
acid
aqueou
solut
ferrocenyl
analogu
seem
unstabl
lead
format
presum
inact
carbenium
among
fourteen
ferrocen
atovaquon
conjug
synthes
test
toxoplasma
gondii
p
falciparum
compound
figur
aliphat
chain
carbon
atom
activ
ato
gondii
clone
known
carri
mutat
ubiquinon
bind
pocket
cyt
b
concern
p
falciparum
product
appear
activ
cq
sensit
resist
strain
remain
less
activ
atovaquon
ferrocenyl
sugar
synthes
start
ellagitanin
antimalari
properti
per
deriv
show
antimalari
activ
valu
micromolar
rare
submicromolar
rang
anoth
attempt
inhibit
p
falciparum
hexos
transport
pfht
express
heterolog
system
xenop
oocyt
deriv
perform
product
fail
show
inhibitori
effect
upon
ferrocenyl
chalcon
synthes
among
compound
antimalari
activ
micromolar
interestingli
incorpor
ferrocen
moieti
chalcon
templat
found
enhanc
role
process
involv
free
author
suggest
therefor
ferrrocen
may
particip
redox
reaction
relat
antimalari
recent
attempt
improv
revers
properti
strychnobrasilin
led
synthesi
conjug
show
vitro
synergi
cq
resist
clone
fail
show
activ
vivo
test
associ
cq
p
yoelii
clone
suppress
summari
among
ferrocen
antimalari
synthes
far
deriv
found
promis
usual
activ
cq
sensit
clone
p
falciparum
lesser
extent
artemisiten
deriv
show
interest
properti
remain
best
equal
artemisinin
combin
ferrocen
known
antimalari
molecul
fail
provid
real
lead
develop
new
drug
candid
enter
pharmaceut
develop
process
crystallin
state
inde
molecul
amorph
state
gener
exhibit
greater
chemic
instabl
enhanc
dissolut
rate
alter
mechan
properti
greater
hygroscop
neutral
fq
select
drug
develop
fq
becom
di
proton
enter
acid
environ
stomach
basic
fq
crystal
monoclin
space
group
solid
state
fq
stabil
strong
intramolecular
hydrogen
bond
anilino
nitrogen
atom
tertiari
nitrogen
atom
side
chain
figur
nevertheless
absent
polar
solvent
water
proton
flipflop
may
help
transport
fq
hydrophob
membran
cation
fq
form
stabl
dimer
structur
solid
state
also
process
water
singularli
driven
nonbond
fq
possess
planar
chiral
due
substitut
ferrocen
moieti
figur
pure
enantiom
obtain
enzymat
resolut
use
optic
isom
equal
activ
vitro
p
falciparum
nanomolar
concentr
vivo
enantiom
slightli
less
activ
racem
mixtur
cq
sensit
cq
resist
p
vinckei
vinckei
suggest
addit
synerget
effect
enantiom
moreov
display
better
cur
effect
suggest
differ
pharmacokinet
properti
illustr
figur
metabol
pathway
fq
base
experi
use
anim
human
hepat
model
propos
fq
metabol
via
major
dealkyl
pathway
fq
fq
minor
metabol
pathway
also
identifi
cytochrom
isoform
possibl
patient
isoform
mainli
involv
fq
oxid
activ
two
main
metabolit
decreas
compar
fq
howev
activ
deriv
significantli
higher
cq
strain
deriv
remain
activ
cq
two
metabolit
present
signific
concentr
blood
administr
fq
involv
global
antimalari
activ
fq
fq
respond
neg
ame
fetax
frog
embryo
teratogenesi
assay
xenopu
test
fq
also
test
neg
micronucleu
vitro
vivo
assay
conduct
glp
standard
contrari
kind
experi
cq
found
weakli
mutagen
although
mode
action
still
unknown
cq
report
possess
strong
antivir
effect
sever
acut
respiratori
syndrom
sar
caus
context
fq
evalu
activ
felin
human
sar
coronaviru
compar
parent
drug
cq
besid
antimalari
activ
fq
effect
inhibitor
replic
vero
cell
within
concentr
rang
nevertheless
low
select
index
allow
pharmaceut
far
fq
test
differ
laboratori
p
falciparum
seven
seri
field
isol
total
gabon
seneg
figur
tabl
show
mean
observ
differ
studi
signific
correl
appear
cq
fq
mean
valu
figur
research
show
weak
correl
cq
fq
respons
differ
field
isol
studi
without
signific
consequ
clinic
applic
recent
investig
demonstr
probabl
influenc
initi
parasitaemia
start
assay
isol
test
ident
initi
parasitaemia
use
covari
analysi
take
account
initi
parasitaemia
show
correl
respons
fq
vivo
experi
perform
rodent
plasmodium
speci
show
whatev
suscept
strain
cq
way
administr
tabl
cur
dose
fq
remain
demonstr
power
activ
drug
high
oral
bioavail
two
major
qualiti
develop
drug
mechan
action
fq
studi
comparison
cq
year
mechan
cq
subject
lot
discuss
argument
nevertheless
strong
evid
action
cq
correl
local
food
vacuol
parasit
associ
fq
form
complex
hematin
stoichiometri
free
energi
associ
estim
kcal
lead
conclus
noncoval
interact
weak
favor
also
note
valu
similar
previous
report
cq
moreov
presenc
fq
hematin
longer
convert
inhibit
format
obtain
fq
equival
rel
hematin
wherea
cq
clearli
show
fq
strong
inhibitor
format
even
potent
molecular
electrostat
potenti
mep
surfac
comput
level
theori
diproton
fq
cq
fq
cq
show
consider
similar
quinolin
area
part
molecul
thought
interact
hematin
stack
interact
similar
mode
interact
activ
drug
fq
cq
hematin
get
better
understand
contribut
ferrocen
moieti
antimalari
activ
fq
also
estim
physicochem
properti
appar
partit
coeffici
log
cq
fq
measur
vacuolar
cytosol
ph
cytosol
ph
fq
lipophil
cq
wherea
differ
lipophil
slight
vacuolar
ph
pk
valu
drug
allow
us
specul
fq
accumul
lower
concentr
howev
altern
method
base
logd
valu
led
contradictori
result
experiment
determin
straightforward
accumul
fq
insid
food
vacuol
urgent
need
solv
problem
conclus
activ
fq
may
due
one
rout
figur
mechan
action
part
similar
cq
base
inhibit
effect
format
result
inhibit
hemozoin
format
anoth
hand
redox
activ
ferrocen
ferricinium
implic
radic
gener
exclud
current
investig
moreov
metallocen
alter
shape
volum
lipophil
basic
electron
profil
parent
molecul
consequ
pharmacodynam
behavior
strong
activ
fq
clone
isol
p
falciparum
suggest
fundament
differ
interact
resist
mechan
parasit
induct
resist
fq
method
propos
deriv
test
test
p
yoelii
ns
figur
origin
clone
pycq
clone
pycqr
deriv
week
cq
pressur
mg
cq
modifi
increas
mg
continu
cq
pressur
remain
stabl
mg
resist
revers
verapamil
pycqr
sensit
remain
unchang
toward
mf
fq
pycqr
line
pyfqr
line
deriv
fq
pressur
mg
pyfqr
line
present
multiresist
phenotyp
mg
cq
mf
fq
partial
revers
verapamil
cq
resist
fq
mf
fix
genet
disappear
serial
passag
fq
pressur
remov
also
lost
cryoconserv
growth
pyfqr
line
slow
mous
reticulocyt
select
invad
pcr
amplif
dna
fragment
show
presenc
gene
mutat
alreadi
associ
resist
phenotyp
variou
antimalari
plasmodium
falciparum
ortholog
gene
pycrt
gene
mutat
involv
cq
resist
plasmodium
falciparum
result
show
fq
resist
obtain
rodent
malaria
parasit
fit
cost
resist
extrem
high
growth
limit
slow
sometim
mous
succe
clear
parasit
without
treatment
put
mechan
involv
resist
probabl
differ
defin
p
falciparum
cq
resist
risk
resist
human
plasmodium
speci
fq
might
question
basi
result
obtain
rodent
strain
studi
field
isol
show
suscept
p
falciparum
suscept
fq
relat
pfcrt
gene
phenotyp
level
express
expos
p
falciparum
strain
continu
pressur
nm
fq
yield
viabl
resist
clone
transcient
growth
observ
parasit
unabl
maintain
cultur
even
absenc
complementari
experi
carri
similar
experiment
condit
presenc
nm
fq
concentr
slightli
vitro
strain
fail
select
viabl
resist
clone
transcient
growth
observ
previou
experi
unpublish
data
observ
show
biolog
fit
cost
fq
resist
high
p
falciparum
absenc
continu
drug
pressur
potenti
resist
parasit
easili
concurrenc
nonresist
parasit
ferroquin
uniqu
metallocen
drug
candid
emerg
collabor
french
discoveri
project
advanc
malaria
drug
candid
develop
ferroquin
extrem
activ
p
falciparum
phase
clinic
trial
complet
recommend
phase
ii
clinic
trial
begin
examin
efficaci
combin
therapi
act
artesun
fq
malaria
